SCHEMBL21765544

SCHEMBL21765544

COC(=O)C(C(=O)OC)C(=O)C1(n2ccc(-c3ccc(Cl)cc3)c2)CCCCC1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.39
SLC6A3 Q01959 4/20 0.36
SLC6A2 P23975 2/20 0.36
KDM4E B2RXH2 1/20 0.35
ITGB1 P05556 1/20 0.33
ITGA4 P13612 1/20 0.33
ITGB7 P26010 1/20 0.33
MAPT P10636 1/20 0.32
SLC6A4 P31645 1/20 0.32
TP53 P04637 1/20 0.32
NOS3 P29474 1/20 0.32
NOS1 P29475 1/20 0.32
NOS2 P35228 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
HSD11B1 P28845 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21765536 0.89 ITGB1 (0.33) SLC6A3KDM4EITGB1ITGA4ITGB7
SCHEMBL21765802 0.89 ACHE (0.39) ACHESLC6A3MAPTMEN1KMT2A
SCHEMBL21765779 0.88 ALDH1A1 (0.37) ACHESLC6A3SLC6A2ITGB1ITGA4
SCHEMBL21765788 0.87 ACHE (0.37) ACHEKDM4EMEN1KMT2A
SCHEMBL21747401 0.86 KDM4E (0.35) SLC6A2KDM4EITGB1ITGA4ITGB7
SCHEMBL21765552 0.85 ACHE (0.37) ACHESLC6A3SLC6A2SLC6A4MEN1
SCHEMBL25544096 0.84 KDM4E (0.36) SLC6A3SLC6A2KDM4ESLC6A4MEN1
SCHEMBL21747255 0.79 HSD11B1 (0.38) SLC6A3SLC6A2KDM4EHSD11B1
SCHEMBL21765773 0.79 ACHE (0.36) ACHESLC6A3SLC6A2KDM4EITGB1
SCHEMBL21747240 0.78 MMP1 (0.37) ACHESLC6A3SLC6A2KDM4ESLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11970495-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2024-04-30 US disclosed
US-11945817-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2024-04-02 US disclosed
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-17 US disclosed
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-17 US disclosed
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-03 US disclosed
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-03 US disclosed
US-11655249-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2023-05-23 US disclosed
US-11655249-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2023-05-23 US disclosed
EP-3613742-B1 INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE KIND PHARMACEUTICAL (CN) 2022-12-07 EP disclosed
US-20210253570-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2021-08-19 US disclosed
CN-113004271-A Indolizine derivative and application thereof in medicine 杭州安道药业有限公司 2021-06-22 CN disclosed
US-11021478-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2021-06-01 US disclosed
CN-108484598-B Indolizine derivative and application thereof in medicine 杭州安道药业有限公司 2021-03-02 CN disclosed
US-20200165242-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2020-05-28 US disclosed
EP-3613742-A1 INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE Kind Pharmaceutical (CN) 2020-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 ACHE 992/4885SLC6A3 132/4885SLC6A2 48/4885
US-11021478-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 ACHE 992/4885SLC6A3 132/4885SLC6A2 48/4885
US-11970495-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 ACHE 992/4885SLC6A3 132/4885SLC6A2 48/4885
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 ACHE 992/4885SLC6A3 132/4885SLC6A2 48/4885
US-11945817-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 ACHE 992/4885SLC6A3 132/4885SLC6A2 48/4885
US-20210253570-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 ACHE 992/4885SLC6A3 132/4885SLC6A2 48/4885
US-11655249-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 ACHE 992/4885SLC6A3 132/4885SLC6A2 48/4885
US-20200165242-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 ACHE 992/4885SLC6A3 132/4885SLC6A2 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.